Co-editor-in-Chief Howard S. Hochster, MD, highlights exciting clinical trials that may set future standards for adjuvant therapy selection in colon cancer.
Neil M. Iyengar, MD
Co-Editor in Chief
Co-Director, Breast Medical Oncology
Director, Cancer Survivorship Services
Associate Professor of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Iyengar is part of the breast oncology team at Winship Cancer Institute at Emory University. He graduated from the University of Illinois at Chicago and completed his residency at the University of Chicago Medical Center and his fellowship at MSKCC. Iyengar has been granted with many prestigious awards including the Career Development Award from Conquer Cancer at the American Society of Clinical Oncology Foundation and Breast Cancer Research Foundation Investigator.
Advertisement
Howard S. Hochster, MD, considers drug price negotiation in this month's Letter to the Readers.
In this month's Letter to the Readers, ONCOLOGy co-editor-in-chief Howard Hochster, MD, reviews the implications of legal disputes surrounding patents for CRISPR technology.
In this month’s Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, reviews results of the CIRCULATE-Japan clinical trial that were presented at the 2022 Gastrointestinal Cancers Symposium.
ONCOLOGY® co-editor-in-chief Howard S. Hochster, MD, reviews research on delays in oncology care as a result of the COVID-19 pandemic.
CancerNetwork®’s podcast hosted 2 experts to discuss the current state of biosimilar prescriptions and the need for change to improve the system overall.
In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the utility of next-generation sequencing in pancreatic ductal adenocarcinoma.
In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the development of mRNA technology, especially as it applies to vaccines against COVID-19.
Unprecedented efforts from researchers and pharmaceutical engineers have brought about safe, effective vaccines, in record development times; now the focus must be on a federally coordinated program to administer those injections in the most efficient manner possible.
Advertisement
Advertisement
